Orexo AB publ

Orexo AB publ

Improves lives for patients suffering from mental illness and substance use disorder 💚

Founded 1995 Sweden

Sweden 97 employees Post-IPO Debt Total: $571.60M Biotechnology, Health Care +1

Orexo AB publ is a Swedish pharmaceutical company founded in 1995 with a mission to improve the lives of patients suffering from mental illness and substance use disorder. With over 25 years of experience, Orexo has developed improved pharmaceuticals based on proprietary formulation technologies, addressing significant medical needs. The company focuses on providing innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases in the US market and collaborates with leading partners to develop and commercialize products targeting other therapeutic areas worldwide. Orexo's total net sales in 2022 amounted to SEK 624 million, with 126 employees and is listed on Nasdaq Stockholm's main list, while also available as an ADR on OTCQX (ORXOY) in the US. In March 2024, Orexo secured a kr500.00MPost-IPO Debt investment. The company's dedication to addressing critical health challenges and its successful track record in the pharmaceutical industry make it an attractive opportunity for investors seeking to contribute to the advancement of healthcare solutions. Orexo's commitment to driving positive outcomes for patients aligns with the growing focus on mental health and addiction treatment, positioning the company for potential growth and impact in the healthcare sector. Investors looking to support innovative pharmaceutical solutions and address unmet medical needs may find Orexo to be a compelling investment opportunity. For more information about Orexo, please visit its website: www.orexo.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	kr500.00M	-		13 Mar 2024
Post IPO Equity	$50.60M	-		29 Aug 2014
Post IPO Equity	Undisclosed	1	Novo Holdings	01 Apr 2010
Series B	€21.00M	5	HealthCap, Sofinnova Investments +3	17 Jan 2003

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Debt

kr500.00M

13 Mar 2024

Post IPO Equity

$50.60M

29 Aug 2014

Post IPO Equity

Undisclosed

Novo Holdings

01 Apr 2010

Series B

€21.00M

HealthCap, Sofinnova Investments +3

17 Jan 2003

FAQ About Orexo AB publ

Improves lives for patients suffering from mental illness and substance use disorder 💚

Orexo AB publ was founded in 1995.

Orexo AB publ is headquartered in Sweden.

Orexo AB publ operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Pharmaceuticals, Specialty Pharmaceuticals, Drug Delivery and Research & Development.

Orexo AB publ has approximately 97 employees.

Orexo AB publ has completed 4 funding rounds, raising a total of $571.60M. The latest funding stage is Post-IPO Debt.

Top alternatives and competitors to Orexo AB publ include BioCorRx Pharmaceuticals Inc., InterveXion Therapeutics, Sen-Jam Pharmaceutical, Pear Therapeutics, Awakn Life Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Orexo AB publ and BioCorRx Pharmaceuticals Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Orexo AB publ

Funding Rounds & Investors (4)

Orexo AB publ Alternatives & Competitors

FAQ About Orexo AB publ